Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Schrödinger, Inc. (SDGR:NASDAQ), powered by AI.
Schrödinger, Inc. is currently trading at $15.76. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Schrödinger, Inc. on Alpha Lenz.
Schrödinger, Inc.'s P/E ratio is -11.2.
“Schrödinger, Inc. trades at a P/E of -11.2 (undervalued) with modest ROE of -26.3%. 3Y revenue CAGR of 12.2% highlights clear growth momentum.”
Ask for details →Schrodinger Inc. is a prominent player in the life sciences and materials sciences sectors, primarily recognized for its pioneering software applications. The company focuses on developing cutting-edge computational platforms to accelerate drug discovery and material design processes. Leveraging its proprietary physics-based computational technology, Schrodinger provides a comprehensive suite of tools that enable researchers to predict molecular behavior with high accuracy. This innovative approach not only enhances the efficiency and efficacy of drug development pipelines but also contributes to advancements in various industries such as pharmaceuticals, biotechnology, chemicals, and electronics. Schrodinger's software solutions are utilized by a diverse customer base, from academic researchers and biotechnology startups to large pharmaceutical companies, highlighting its significant impact on scientific research and development. Headquartered in New York City, Schrodinger continues to play a critical role in transforming scientific methodologies and expediting the journey from conceptualization to product realization in the market.
“Schrödinger, Inc. trades at a P/E of -11.2 (undervalued) with modest ROE of -26.3%. 3Y revenue CAGR of 12.2% highlights clear growth momentum.”
Ask for details →Schrödinger, Inc. (ticker: SDGR) is a company listed on NASDAQ in the Healthcare sector (Health Information Services). It has approximately 891 employees. Market cap is $1.2B.
The current price is $15.76 with a P/E ratio of -11.21x and P/B of 3.18x.
ROE is -26.29% and operating margin is -65.23%. Annual revenue is $256M.